Checkmate 77T：围手术期化学免疫疗法在早期 NSCLC 中表现优异。

IF 12.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2024-08-09 DOI:10.1016/j.medj.2024.06.012

Danielle Brazel, Misako Nagasaka

引用次数: 0

摘要

大约每 4 名 NSCLC 患者中就有 1 人患有可切除的疾病。虽然手术有可能治愈，但仍有 30%-50% 的患者会复发。研究表明，新辅助治疗、辅助治疗和围手术期化疗免疫疗法可改善预后。Checkmate 77T 试验探讨了围手术期铂类化疗加尼夫单抗、手术切除、然后辅助尼夫单抗是否能进一步改善包括 EFS 在内的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Checkmate 77T: Perioperative chemoimmunotherapy outperforms in early-stage NSCLC.

Approximately 1 in 4 patients with NSCLC present with resectable disease. Although surgery is potentially curative, 30%-50% of patients relapse. Studies have shown that neoadjuvant, adjuvant, and perioperative chemoimmunotherapy improve outcomes. The Checkmate 77T trial explored if perioperative platinum-based chemotherapy plus nivolumab, surgical resection, then adjuvant nivolumab further improved outcomes including EFS.¹.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.

Checkmate 77T： 围手术期化学免疫疗法在早期 NSCLC 中表现优异。

摘要

Checkmate 77T：围手术期化学免疫疗法在早期 NSCLC 中表现优异。